drugset / Trial / NCT01021358

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

NCT01021358

Phase 1 Completed 12 enrolled Abbott
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a single dose, open-label, single or multiple center study to determine the interaction of ketoconazole with ABT-263 in approximately 12 subjects with cancer.

Timeline

Start
2010-01
Primary completion
2010-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketoconazole Small molecule
Subject Navitoclax Small molecule